Abstract

Resveratrol has beneficial effects on aging, inflammation and metabolism, which are thought to result from activation of the lysine deacetylase, sirtuin 1 (SIRT1), the cAMP pathway, or AMP-activated protein kinase. Here we report that resveratrol acts as a pathway-selective estrogen receptor-α (ERα) ligand to modulate the inflammatory response but not cell proliferation. A crystal structure of the ERα ligand-binding domain (LBD) as a complex with resveratrol revealed a unique perturbation of the coactivator-binding surface, consistent with an altered coregulator recruitment profile. Gene expression analyses revealed significant overlap of TNFα genes modulated by resveratrol and estradiol. Furthermore, the ability of resveratrol to suppress interleukin-6 transcription was shown to require ERα and several ERα coregulators, suggesting that ERα functions as a primary conduit for resveratrol activity.

Article and author information

Author details

  1. Jerome C Nwachukwu

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Sathish Srinivasan

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Nelson E Bruno

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Alex A Parent

    University of Illinois, Urbana, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Travis S Hughes

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Julie A Pollock

    University of Illinois, Urbana, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Olsi Gjyshi

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Valerie Cavett

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jason Nowak

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Ruben D Garcia-Ordonez

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. René Houtman

    PamGene International, Den Bosch, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  12. Patrick R Griffin

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Douglas J Kojetin

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. John A Katzenellenbogen

    University of Illinois, Urbana, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Michael D Conkright

    The Scripps Research Institute, Jupiter, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Kendall W Nettles

    The Scripps Research Institute, Jupiter, United States
    For correspondence
    knettles@scripps.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Leemor Joshua-Tor, Cold Spring Harbor Laboratory, United States

Version history

  1. Received: December 12, 2013
  2. Accepted: April 5, 2014
  3. Accepted Manuscript published: April 25, 2014 (version 1)
  4. Version of Record published: May 13, 2014 (version 2)

Copyright

© 2014, Nwachukwu et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,216
    views
  • 558
    downloads
  • 108
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jerome C Nwachukwu
  2. Sathish Srinivasan
  3. Nelson E Bruno
  4. Alex A Parent
  5. Travis S Hughes
  6. Julie A Pollock
  7. Olsi Gjyshi
  8. Valerie Cavett
  9. Jason Nowak
  10. Ruben D Garcia-Ordonez
  11. René Houtman
  12. Patrick R Griffin
  13. Douglas J Kojetin
  14. John A Katzenellenbogen
  15. Michael D Conkright
  16. Kendall W Nettles
(2014)
Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network
eLife 3:e02057.
https://doi.org/10.7554/eLife.02057

Share this article

https://doi.org/10.7554/eLife.02057

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Damien M Rasmussen, Manny M Semonis ... Nicholas M Levinson
    Research Article

    The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

    1. Structural Biology and Molecular Biophysics
    Nicholas James Ose, Paul Campitelli ... Sefika Banu Ozkan
    Research Article

    We integrate evolutionary predictions based on the neutral theory of molecular evolution with protein dynamics to generate mechanistic insight into the molecular adaptations of the SARS-COV-2 spike (S) protein. With this approach, we first identified candidate adaptive polymorphisms (CAPs) of the SARS-CoV-2 S protein and assessed the impact of these CAPs through dynamics analysis. Not only have we found that CAPs frequently overlap with well-known functional sites, but also, using several different dynamics-based metrics, we reveal the critical allosteric interplay between SARS-CoV-2 CAPs and the S protein binding sites with the human ACE2 (hACE2) protein. CAPs interact far differently with the hACE2 binding site residues in the open conformation of the S protein compared to the closed form. In particular, the CAP sites control the dynamics of binding residues in the open state, suggesting an allosteric control of hACE2 binding. We also explored the characteristic mutations of different SARS-CoV-2 strains to find dynamic hallmarks and potential effects of future mutations. Our analyses reveal that Delta strain-specific variants have non-additive (i.e., epistatic) interactions with CAP sites, whereas the less pathogenic Omicron strains have mostly additive mutations. Finally, our dynamics-based analysis suggests that the novel mutations observed in the Omicron strain epistatically interact with the CAP sites to help escape antibody binding.